Viewpoint of the European pediatric societies over SARS-CoV-2 Vaccination in Children under age 12 amid return to school and the surging virus variants.

Since its first appearance in the Wuhan region of China in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a public health and a socio-economic crisis worldwide1. According to the WHO Coronavirus (COVID-19) dashboard, as of September 2021, there have been more than 217 million confirmed cases and 4.5 million deaths reported2. Mass vaccination campaigns against SARS-CoV-2 are ongoing worldwide. Currently, 5.38 billion doses have been administered globally, 39.9% of the world population has received at least one dose of a COVID-19 vaccine and about 40 million are administered each day.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Source Type: research

Related Links:

NEW BRUNSWICK, N.J., October 15, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson &Johnson COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine. The vote was based on findings from two Company clinical trials, including the Phase 3 ENSEMBLE 2 study, which evaluated a booster dose of the Johnson &J...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Purpose of review The COVID-19 global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a dramatic impact that is still ongoing around the world. Cystic fibrosis (CF) has been identified as a possible risk factor of poor outcome. Recent findings Data collected by multiple National CF registries around the world have indicated that persons with CF (PwCF) are not more likely to be affected by SARS-CoV-2 than the general population. The course of SARS-CoV-2 is usually mild in PwCF who are relatively young. Severe outcomes have been described in patients with low lung functi...
Source: Current Opinion in Pulmonary Medicine - Category: Respiratory Medicine Tags: CYSTIC FIBROSIS: Edited by Peter J. Barry and Barry J. Plant Source Type: research
CONCLUSION: Together, the in silico analysis revealed the predicted structure of partial S protein, immunogenic properties, and possible regions for S protein of SARS-CoV-2 and provides a valuable prelude for engineering the targeted vaccine or drug against B.1.617.1 variant of SARS-CoV-2.PMID:34651048 | PMC:PMC8510791 | DOI:10.1155/2021/7251119
Source: Cell Research - Category: Cytology Authors: Source Type: research
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over 100 million infections and millions of deaths. Effective vaccines remain the best hope of curtailing SARS-CoV-2 transmission, morbidity, and mortality. The vaccines in current use require cold storage and sophisticated manufacturing capacity, which complicates their...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Immunology and Inflammation, Coronavirus (COVID-19) Biological Sciences Source Type: research
In this study, we investigated the current research progress in combating SARS-CoV-2 infection. Based on the published research findings, we first elucidated, at the molecular level, SARS-CoV-2 viral structures, potential viral host-cell-invasion and pathogenic mechanisms, main virus-induced immune responses, and emerging SARS-CoV-2 variants. We then focused on the main virus- and host-based potential targets, summarized and categorized effective inhibitory molecules based on drug development strategies for COVID-19, that can guide efforts for the identification of new drugs and treatment for this problematic disease. Curr...
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
Cell Mol Immunol. 2021 Oct 13:1-8. doi: 10.1038/s41423-021-00774-w. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an ongoing pandemic that poses a great threat to human health worldwide. As the humoral immune response plays essential roles in disease occurrence and development, understanding the dynamics and characteristics of virus-specific humoral immunity in SARS-CoV-2-infected patients is of great importance for controlling this disease. In this review, we summarize the characteristics of the humoral immune response after SA...
Source: Cellular and Molecular Immunology - Category: Molecular Biology Authors: Source Type: research
In this study, we investigated the current research progress in combating SARS-CoV-2 infection. Based on the published research findings, we first elucidated, at the molecular level, SARS-CoV-2 viral structures, potential viral host-cell-invasion and pathogenic mechanisms, main virus-induced immune responses, and emerging SARS-CoV-2 variants. We then focused on the main virus- and host-based potential targets, summarized and categorized effective inhibitory molecules based on drug development strategies for COVID-19, that can guide efforts for the identification of new drugs and treatment for this problematic disease. Curr...
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
This study aims to systematically review and evaluate the immunogenicity and safety of COVID-19 vaccines compared with control arms in the healthy adult population.
Source: Value in Health - Category: International Medicine & Public Health Authors: Tags: Systematic Literature Review Source Type: research
This study attempted to assess the prevalence of antibodies to SARS-CoV-2 among blood donors in Delhi, India during the pre-vaccination period.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
ConclusionSARS-CoV-2 specific RNAi in conjunction with systemic delivery of compstatin will be an effective two-pronged strategy to combat local and systemic immune responses in both symptomatic and asymptomatic COVID-19 patients.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Tags: REVIEW ARTICLE Source Type: research
More News: Children | China Health | Coronavirus | COVID-19 | International Medicine & Public Health | Pediatrics | Respiratory Medicine | SARS | Vaccines